teloxol

Teloxol is a small molecule tetrahydroisoquinoline derivative, specifically (±)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline, developed for the treatment of silicosis. It is primarily investigated as teloxol hydrochloride by the National Institute for Occupational Health and Poison Control of the Chinese Center for Disease Control and Prevention. The drug functions as a calcium channel blocker and exhibits anti-fibrotic and anti-inflammatory properties. It is designed to inhibit the progression of pulmonary fibrosis by suppressing fibroblast proliferation, collagen synthesis, and the production of pro-inflammatory and pro-fibrotic cytokines such as tumor necrosis factor-alpha (TNF-α) and transforming growth factor-beta 1 (TGF-β1). Teloxol has been evaluated in Phase II clinical trials in China, focusing on its efficacy and safety in patients with stage I–II silicosis.

Other names

teloxol hydrochlorideteloxolum